Biomea Fusion launches stock and warrant offering, size undisclosed
What's the deal? Biomea Fusion (BMEA) has commenced an underwritten public offering of common stock, plus pre-funded warrants for certain investors in lieu of shares. The company did not disclose the amount it aims to raise.
Who's involved? All shares and warrants will be sold by Biomea itself. Konik Capital PartnersDealroom has a profile for this one. Try Dealroom →, a division of T.R. Winston & CompanyDealroom has a profile for this one. Try Dealroom →, is acting as sole underwriter.
Why now? The raise follows recent clinical progress for the biotech, which completed enrollment in its COVALENT-211 Phase 2 trial of icovamenib in insulin-deficient type 2 diabetes. It also completed a key Phase 2 trial in type 1 diabetes.
The signal: As a post-IPO equity raise, the offering gives Biomea fresh capital to advance a clinical pipeline that is drawing investor attention around its diabetes programs.
Read more: Business Insider
Image credit: Generated with Gemini
